المؤلفون: Ryo Yamamoto, Nobuhiro Okagaki, Hiroto Sakamoto, Yuuma Tanaka, Atsushi Takeda, Naoto Maruguchi, Satoshi Nakamura, Kazuki Matsumura, Masakuni Ueyama, Naoya Ikegami, Yusuke Kaji, Seishu Hashimoto, Eisaku Tanaka, Yoshio Taguchi, Wataru Maruyama, Hiroyuki Katsuragawa, Shinji Sumiyoshi, Takashi Hajiro

المصدر: Internal Medicine. 2024, 63(4):559-563

المؤلفون: Atsushi Takeda, Eisaku Tanaka, Hiroto Sakamoto, Kazuki Matsumura, Masakuni Ueyama, Naoto Maruguchi, Naoya Ikegami, Nobuhiro Okagaki, Ryo Yamamoto, Satoshi Nakamura, Seishu Hashimoto, Takashi Hajiro, Yoshio Taguchi, Yuma Tanaka, Yusuke Kaji

المصدر: Internal Medicine. 2023, 62(22):3291

المؤلفون: Atsushi Takeda, Eisaku Tanaka, Kazuki Matsumura, Masakuni Ueyama, Naoto Maruguchi, Ryo Yamamoto, Satoshi Nakamura, Satoshi Noma, Seishu Hashimoto, Takashi Hajiro, Takehiro Yasuda, Takeshi Kubo, Yoichiro Kobashi, Yoshio Taguchi, Yusuke Kaji, 上山 維晋, 中村 哲史, 丸口 直人, 久保 武, 加持 雄介, 安田 武洋, 小橋 陽一郎, 山本 亮, 松村 和紀, 橋本 成修, 武田 淳志, 田中 栄作, 田口 善夫, 羽白 高, 野間 惠之

المصدر: 天理医学紀要 / Tenri Medical Bulletin. 2022, 25(2):98

المؤلفون: Atsushi Takeda, Eisaku Tanaka, Gen Honjo, Kazuki Matsumura, Maruguchi Naoto, Masakuni Ueyama, Ryo Yamamoto, Satoru Terada, Satoshi Nakamura, Seishu Hashimoto, Shinji Sumiyoshi, Takashi Hajiro, Takashi Inao, Takehiro Yasuda, Yoichiro Kobashi, Yoshio Taguchi, Yusuke Kaji, 上山 維晋, 中村 哲史, 丸口 直人, 住吉 真治, 加持 雄介, 安田 武洋, 寺田 悟, 小橋 陽一郎, 山本 亮, 本庄 原, 松村 和紀, 橋本 成修, 武田 淳志, 田中 栄作, 田口 善夫, 稲尾 崇, 羽白 高

المصدر: 天理医学紀要 / Tenri Medical Bulletin. 2022, 25(1):22

المؤلفون: Takafumi Niwamoto, Tomohiro Handa, Yuko Murase, Yoshinari Nakatsuka, Kiminobu Tanizawa, Yoshio Taguchi, Hiromi Tomioka, Keisuke Tomii, Hideo Kita, Michihiro Uyama, Michiko Tsuchiya, Masahito Emura, Tetsuji Kawamura, Naoki Arai, Machiko Arita, Kazuko Uno, Akihiko Yoshizawa, Ryuji Uozumi, Izumi Yamaguchi, Fumihiko Matsuda, Kazuo Chin, Toyohiro Hirai

المصدر: Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)

مصطلحات موضوعية: CTACK, Cutaneous T-cell-attracting chemokine, CCL27, IPF, Idiopathic pulmonary fibrosis, Biomarker, Diseases of the respiratory system, RC705-779

الوصف: Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease that leads to respiratory failure and death. Although there is a greater understanding of the etiology of this disease, accurately predicting the disease course in individual patients is still not possible. This study aimed to evaluate serum cytokines/chemokines as potential biomarkers that can predict outcomes in IPF patients. Methods A multi-institutional prospective two-stage discovery and validation design using two independent cohorts was adopted. For the discovery analysis, serum samples from 100 IPF patients and 32 healthy controls were examined using an unbiased, multiplex immunoassay of 48 cytokines/chemokines. The serum cytokine/chemokine values were compared between IPF patients and controls; the association between multiplex measurements and survival time was evaluated in IPF patients. In the validation analysis, the cytokines/chemokines identified in the discovery analysis were examined in serum samples from another 81 IPF patients to verify the ability of these cytokines/chemokines to predict survival. Immunohistochemical assessment of IPF-derived lung samples was also performed to determine where this novel biomarker is expressed. Results In the discovery cohort, 18 cytokines/chemokines were significantly elevated in sera from IPF patients compared with those from controls. Interleukin-1 receptor alpha (IL-1Rα), interleukin-8 (IL-8), macrophage inflammatory protein 1 alpha (MIP-1α), and cutaneous T-cell-attracting chemokine (CTACK) were associated with survival: IL-1Rα, hazard ratio (HR) = 1.04 per 10 units, 95% confidence interval (95% CI) 1.01–1.07; IL-8, HR = 1.04, 95% CI 1.01–1.08; MIP-1α, HR = 1.19, 95% CI 1.00–1.36; and CTACK, HR = 1.12 per 100 units, 95% CI 1.02–1.21. A replication analysis was performed only for CTACK because others were previously reported to be potential biomarkers of interstitial lung diseases. In the validation cohort, CTACK was associated with survival: HR = 1.14 per 100 units, 95% CI 1.01–1.28. Immunohistochemistry revealed the expression of CTACK and CC chemokine receptor 10 (a ligand of CTACK) in airway and type II alveolar epithelial cells of IPF patients but not in those of controls. Conclusions CTACK is a novel prognostic biomarker of IPF. Trial registration None (because of no healthcare intervention)

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1465-993XTest

الوصول الحر: https://doaj.org/article/272ec9eb56884ab48e37f489bee9a453Test

المؤلفون: Tsuyoshi Shirai, Yoshinori Tanino, Takefumi Nikaido, Yotaro Takaku, Seishu Hashimoto, Yoshio Taguchi, Tomohisa Baba, Takashi Ogura, Kensuke Kataoka, Masayuki Nakayama, Yoshihito Yamada, Sayomi Matsushima, Satoshi Nakayama, Yasunari Miyazaki

المصدر: Allergology International, Vol 70, Iss 2, Pp 208-214 (2021)

مصطلحات موضوعية: Bird antigen, Hypersensitivity pneumonitis, ImmunoCAP®, Screening, Specific antigen, Immunologic diseases. Allergy, RC581-607

الوصف: Background: Bird antigens are some of the most relevant antigens in hypersensitivity pneumonitis (HP). Possible sources of bird antigens are bird breeding, feather products and fertilizer with fowl droppings. For the screening and diagnosis of HP, the measurement of bird-specific antibodies should be standardized. The aim of this study was to clarify the utility of serum IgG (sIgG) and IgA (sIgA) antibodies to bird antigens in screening and diagnosing acute/chronic bird-related HP with ImmunoCAP® in multi-centre clinical research. Methods: We executed a clinical performance test by conducting a multi-institutional study to measure the levels of sIgG/sIgA against pigeon, parrot and budgerigar antigens by the ImmunoCAP® system in 29 acute and 46 chronic bird-related HP patients. Results: The levels of sIgG/sIgA against the bird antigens of the three species were significantly higher in subjects with acute bird-related HP and chronic bird-related HP with acute episodes (recurrent type) than in the control subjects. For sIgG, the optimal cutoff values by receiver operating characteristic (ROC) analysis were 24.6 mgA/L for pigeon, 14.0 mgA/L for parrot, and 8.7 mgA/L for budgerigar. By measuring multiple bird antigens and combining sIgG values of two species, the sensitivity and specificity for acute and recurrent-type chronic bird-related HP patients were 85–91% and 73–80%, respectively. For recurrent and insidious types of chronic bird-related HP, the sensitivity and specificity were 48–61% and 73–80%, respectively. Conclusions: Measurement of the levels of sIgG/sIgA against pigeon, budgerigar and parrot antigens by ImmunoCAP® was useful for screening and diagnosis in bird-related HP.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1323893020301283Test; https://doaj.org/toc/1323-8930Test

الوصول الحر: https://doaj.org/article/f5725c167e6a41fe9fbc2d732051f708Test

المؤلفون: Akihiro Ito, Yoshihiro Yamamoto, Yoshikazu Ishii, Akihito Okazaki, Yoshihisa Ishiura, Yukio Kawagishi, Yasuo Takiguchi, Kazuma Kishi, Yoshio Taguchi, Takashi Shinzato, Yasumi Okochi, Ryuji Hayashi, Yoshitaka Nakamori, Yoshiko Kichikawa, Kengo Murata, Hiroaki Takeda, Futoshi Higa, Takayuki Miyara, Keisuke Saito, Takeo Ishikawa, Tadashi Ishida, Kazuhiro Tateda

المصدر: International Journal of Infectious Diseases, Vol 103, Iss , Pp 42-47 (2021)

مصطلحات موضوعية: Diagnosis, Immunoassay, Legionella pneumophila, Pneumonia, Urinary antigen test, Infectious and parasitic diseases, RC109-216

الوصف: Objectives: The aim of this study was to evaluate the diagnostic utility of a novel test kit that could theoretically detect all serogroups of Legionella pneumophila for diagnosing Legionella pneumonia, in comparison with existing kits. Methods: This study was conducted in 16 hospitals in Japan from April 2016 to December 2018. Three urinary antigen test kits were used: the novel kit (LAC-116), BinaxNOW Legionella (Binax), and Q-line Kyokutou Legionella (Q-line). In addition, sputum culture and nucleic acid detection tests and serum antibody tests were performed where possible. The diagnostic accuracy and correlations of the novel kit with the two existing kits were analyzed. Results: In total, 56 patients were diagnosed with Legionella pneumonia. The sensitivities of LAC-116, Binax, and Q-line were 79%, 84%, and 71%, respectively. The overall match rate between LAC-116 and Binax was 96.8% and between LAC-116 and Q-line was 96.4%. One patient had L. pneumophila serogroup 2, and only LAC-116 showed a positive result, whereas Binax and Q-line did not. Conclusions: The novel Legionella urinary antigen test kit was useful for diagnosing Legionella pneumonia. In addition, it could detect Legionella pneumonia caused by non-L. pneumophila serogroup 1.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1201971220323122Test; https://doaj.org/toc/1201-9712Test

الوصول الحر: https://doaj.org/article/99284a67f5e74eaab8d12342d485cd2aTest

المؤلفون: Kimiyuki Ikeda, Hirofumi Chiba, Hirotaka Nishikiori, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Hiroki Sakaguchi, Shogo Miyazawa, Moritaka Suga, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Hiroki Takahashi, Pirfenidone Clinical Study Group in Japan

المصدر: Respiratory Research, Vol 21, Iss 1, Pp 1-12 (2020)

مصطلحات موضوعية: Idiopathic pulmonary fibrosis, Pirfenidone, Biomarker, Surfactant protein D, Diseases of the respiratory system, RC705-779

الوصف: Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease course. The recent advancement of antifibrotic therapy has increased the need for reliable and specific biomarkers. This study aimed to assess alveolar epithelial biomarkers as predictors for the efficacy of the antifibrotic drug pirfenidone. Methods We conducted a post-hoc analysis of the prospective, multicenter, randomized, placebo-controlled, phase 3 trial of pirfenidone in Japan (total, n = 267; pirfenidone, n = 163; placebo, n = 104). Logistic regression analysis was performed to extract parameters that predicted disease progression, defined by a ≥ 10% relative decline in vital capacity (VC) from baseline and/or death, at week 52. For assessment of serum surfactant protein (SP)-D, SP-A and Krebs von den Lungen (KL)-6, all patients were dichotomized by the median concentration of each biomarker at baseline to the high and low biomarker subgroups. Associations of these concentrations were examined with changes in VC at each time point from baseline up to week 52, along with progression-free survival (PFS). Additionally, the effect of pirfenidone treatment on serial longitudinal concentrations of these biomarkers were evaluated. Results In the multivariate logistic regression analysis, body mass index (BMI), %VC and SP-D in the pirfenidone group, and BMI and %VC in the placebo group were indicated as predictors of disease progression. Pirfenidone treatment reduced the decline in VC with statistical significance in the low SP-D and low SP-A subgroups over most of the treatment period, and also prolonged PFS in the low SP-D and low KL-6 subgroups. Furthermore, SP-D levels over time course were reduced in the pirfenidone group from as early as week 8 until the 52-week treatment period compared with the placebo group. Conclusions Serum SP-D was the most consistent biomarker for the efficacy of pirfenidone in the cohort trial of IPF. Serial measurements of SP-D might have a potential for application as a pharmacodynamic biomarker. Trial registration The clinical trial was registered with the Japan Pharmaceutical Information Center (JAPIC) on September 13, 2005 (registration No. JapicCTI-050121; http://Clinicaltrials.jpTest )

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1465-993XTest

الوصول الحر: https://doaj.org/article/b54bb130f11547e4a7e9aad2c5862ed8Test

المؤلفون: Seishu Hashimoto, Eisaku Tanaka, Masakuni Ueyama, Satoru Terada, Takashi Inao, Yusuke Kaji, Takehiro Yasuda, Takashi Hajiro, Tatsuo Nakagawa, Satoshi Noma, Gen Honjo, Yoichiro Kobashi, Noriyuki Abe, Katsuhiko Kamei, Yoshio Taguchi

المصدر: BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-8 (2019)

مصطلحات موضوعية: Botrytis sp., Pulmonary infection, Immunocompetent host, DNA sequence analysis, Infectious and parasitic diseases, RC109-216

الوصف: Abstract Background Botrytis species are well known fungal pathogens of various plants but have not been reported as human pathogens, except as allergenic precipitants of asthma and hypersensitivity pneumonitis. Case presentation The asymptomatic patient was referred because of a nodule revealed by chest X-ray. Computed tomography (CT) showed a cavitary nodule in the right upper lobe of the lung. He underwent wedge resection of the nodule, which revealed necrotizing granulomas and a fungus ball containing Y-shaped filamentous fungi, which was confirmed histopathologically. Culture of the specimen yielded white to grayish cotton-like colonies with black sclerotia. We performed multilocus gene sequence analyses including three single-copy nuclear DNA genes encoding glyceraldehyde-3-phosphate dehydrogenase, heat-shock protein 60, and DNA-dependent RNA polymerase subunit II. The analyses revealed that the isolate was most similar to Botrytis elliptica. To date, the pulmonary Botrytis sp. infection has not recurred after lung resection and the patient did not require any additional medication. Conclusions We report the first case of an immunocompetent patient with pulmonary Botrytis sp. infection, which has not recurred after lung resection without any additional medication. Precise evaluation is necessary for the diagnosis of pulmonary Botrytis infection because it is indistinguishable from other filamentous fungi both radiologically and by histopathology. The etiology and pathophysiology of pulmonary Botrytis infection remains unclear. Further accumulation and analysis of Botrytis cases is warranted.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12879-019-4319-2Test; https://doaj.org/toc/1471-2334Test

الوصول الحر: https://doaj.org/article/1eca734e30554ccebbfe220afe20f3a3Test

المؤلفون: Chisato Izumi, Masashi Amano, Seishu Hashimoto, Takashi Hajiro, Takashi Inao, Toshihiro Tamura, Yodo Tamaki, Yoshio Taguchi

المصدر: Internal Medicine. 2021, 60(20):3289